Home Clinical Examination The Rheumatological System

The Rheumatological System

📋 Key Information Summary

📋
  • A structured rheumatological history should systematically address joint pain character, distribution, symmetry, diurnal variation, morning stiffness duration, and extra-articular features to generate a focused differential diagnosis.
  • Morning stiffness > 1 hour suggests an inflammatory arthritis (rheumatoid arthritis, polymyalgia rheumatica); stiffness < 30 minutes is more consistent with osteoarthritis or mechanical pain.
  • Pattern recognition is paramount: small-joint symmetric polyarthritis (RA), large-joint asymmetric oligoarthritis (gout, reactive arthritis), axial with peripheral enthesitis (SpA), first MTP monoarthritis (gout), DIP-predominant with Heberden's nodes (OA).
  • Raynaud's phenomenon — classic triphasic colour change (white → blue → red) — may be primary (benign) or secondary to systemic sclerosis, SLE, or mixed connective tissue disease; nail-fold capillaroscopy differentiates the two.
  • Sicca symptoms (dry eyes, dry mouth) raise suspicion for Sjögren's syndrome; ask about dental caries, recurrent parotitis, sand-in-eyes sensation, and use of artificial tears.
  • A systematic joint examination must distinguish synovitis (boggy, warm, tender swelling) from bony enlargement (OA), effusion, and periarticular soft-tissue pathology (enthesitis, tenosynovitis, bursitis).
  • Hands and wrists are the single most informative region to examine — inspect for swelling pattern, deformity, muscle wasting, and test grip strength and range of motion.
  • Seronegative spondyloarthritis (psoriatic arthritis, reactive arthritis, ankylosing spondylitis, IBD-associated) is characterised by asymmetric oligoarthritis, enthesitis, dactylitis, axial involvement, and absence of rheumatoid factor.
  • Gout classically presents as acute monoarthritis of the first MTP (podagra), with rapid onset over hours, maximal intensity within 24 hours, and dramatic erythema; urate crystals are negatively birefringent under polarised light microscopy.
  • Signs of systemic connective tissue disease include malar rash (SLE), sclerodactyly and telangiectasia (systemic sclerosis), Gottron's papules and proximal weakness (polymyositis/dermatomyositis), and palpable purpura (vasculitis).
  • Aboriginal and Torres Strait Islander Australians have higher prevalence of gout and rheumatic heart disease; culturally safe assessment and awareness of remote-access barriers to specialist rheumatology care are essential.
  • Red-flag features requiring urgent referral: acute monoarthritis with fever (septic arthritis until proven otherwise), temporal headache + jaw claudication + visual disturbance (giant cell arteritis), progressive scleroderma renal crisis, and any suspected vasculitis with organ-threatening manifestations.

Introduction & Australian Epidemiology

Rheumatic and musculoskeletal diseases (RMDs) are the leading cause of disability in Australia, affecting approximately 7.4 million people — nearly one in three Australians. The Australian Institute of Health and Welfare (AIHW) reports that arthritis and musculoskeletal conditions account for 12% of the total burden of disease, behind only cardiovascular disease and mental health conditions. A systematic approach to rheumatological history and examination is essential for early diagnosis, timely referral to rheumatology, and improved long-term outcomes.

This article provides a structured framework for the clinical assessment of the rheumatological system. It covers the key elements of a focused rheumatological history, recognition of the major patterns of arthritis, a joint-by-joint examination approach, and identification of signs suggestive of systemic connective tissue disease. The emphasis is on clinical skills applicable to Australian primary care, emergency medicine, and general medicine settings.

Condition Estimated Australian Prevalence Key Demographic Notes
Osteoarthritis ~2.1 million (8.3%) Increases with age; most common joint disease; women > men after age 50
Rheumatoid arthritis ~456,000 (1.9%) Peak onset 40–70 years; women : men ≈ 3 : 1
Gout ~624,000 (2.5%) Men > women; higher prevalence in Aboriginal and Torres Strait Islander Australians
Ankylosing spondylitis / axial SpA ~60,000–100,000 Onset typically < 40 years; strong HLA-B27 association; men > women
Systemic lupus erythematosus ~28,000–50,000 Women : men ≈ 9 : 1; higher severity in Aboriginal and Torres Strait Islander and Asian Australians
Systemic sclerosis ~5,000–10,000 Women : men ≈ 4 : 1; limited cutaneous form most common
Psoriatic arthritis ~100,000 ~30% of psoriasis patients; equal sex distribution
⚠️
Window of opportunity: In rheumatoid arthritis, the first 12 weeks of symptom onset represent a critical therapeutic window. Early referral to rheumatology (within 6 weeks of symptom onset where possible) and initiation of disease-modifying therapy (DMARDs) dramatically improves long-term joint outcomes and reduces disability. Any patient with suspected inflammatory arthritis should be referred urgently.

Rheumatological History

A thorough rheumatological history is the most important element in generating a focused differential diagnosis. The clinician must determine whether the pathology is articular (inflammatory vs. non-inflammatory vs. mechanical) or extra-articular, and whether it is localised or systemic. The following domains should be systematically explored.

Joint Pain Characterisation

  • Onset: Acute (hours to days — gout, septic arthritis, crystal arthropathy, trauma) vs. insidious (weeks to months — RA, OA, SpA). Acute monoarthritis is a rheumatological emergency until septic arthritis is excluded.
  • Number of joints involved: Monoarthritis (1 joint), oligoarthritis (2–4 joints), polyarthritis (≥ 5 joints). The number and symmetry guide the differential.
  • Distribution and symmetry: Symmetric small-joint involvement (MCPs, PIPs, wrists) suggests RA; asymmetric large-joint or lower-limb predominant involvement suggests SpA or reactive arthritis; first MTP monoarthritis is classic for gout.
  • Diurnal variation and effect of activity: Inflammatory pain worsens with rest and improves with activity; mechanical/degenerative pain worsens with activity and improves with rest.
  • Migration vs. additive pattern: Migratory arthritis (symptoms move from joint to joint with resolution) suggests acute rheumatic fever, gonococcal arthritis, or lupus. An additive pattern (new joints affected without resolution of prior joints) is more typical of RA.
  • Severity and functional impact: Assess impact on activities of daily living (dressing, gripping, walking, stair climbing, work capacity).

Joint Swelling

  • Soft tissue swelling (boggy, diffuse) — suggests synovitis (inflammatory).
  • Bony hard swelling — osteophytes (OA), bony enlargement.
  • class="guideline-li">Effusion — fluctuant, usually single compartment; may be inflammatory or non-inflammatory.
  • Dactylitis (sausage digit) — entire digit swollen; hallmark of psoriatic arthritis, reactive arthritis, and gout.

Morning Stiffness

💡
Clinical pearl: Morning stiffness duration is one of the most useful discriminating features in rheumatology. Inflammatory arthritis (RA, PMR, active SpA) produces stiffness lasting > 60 minutes, often several hours. Osteoarthritis stiffness typically lasts < 30 minutes ("gelling phenomenon"). Always ask patients to quantify duration — "Do you feel stiff when you wake? How long until you feel loosened up?"

Raynaud's Phenomenon

Raynaud's phenomenon describes episodic vasospasm of the digital arteries triggered by cold exposure or emotional stress, producing a classic triphasic colour change:

  • Phase 1 — White (pallor): Vasospasm causes digital ischaemia; the finger turns white or waxy.
  • Phase 2 — Blue (cyanosis): Deoxygenation of stagnant blood; dusky blue discolouration.
  • Phase 3 — Red (rubor): Reactive hyperaemia as vasospasm resolves; painful red flushing.

Distinguish primary Raynaud's (benign, onset age < 30, symmetric, no tissue damage, no underlying disease) from secondary Raynaud's (asymmetric, age of onset > 30, digital ulceration or pitting, associated with systemic sclerosis, SLE, or other CTD). Investigations including ANA, nail-fold capillaroscopy, and ESR help differentiate the two.

Sicca Symptoms

Sicca symptoms — the sensation of dry eyes (xerophthalmia) and dry mouth (xerostomia) — are the hallmark of Sjögren's syndrome but may also occur secondary to RA, SLE, or as a medication side effect (anticholinergics, antidepressants, diuretics). Key questions include:

  • Do your eyes feel gritty, sandy, or burning? Do you use artificial tears?
  • Do you need to sip water frequently to swallow dry food?
  • Have you had recurrent dental caries or parotid gland swelling?
  • Do you experience vaginal dryness or dry skin?

Systemic and Extra-articular Features

A comprehensive rheumatological history must enquire about systemic features that may indicate connective tissue disease, vasculitis, or systemic inflammation:

Feature Ask About Consider
Skin Rash, photosensitivity, malar erythema, sclerodactyly, psoriasis plaques, purpura, nodules, ulcers SLE, systemic sclerosis, psoriatic arthritis, vasculitis, RA nodules
Eyes Red eye, pain, photophobia, blurred vision, dry eyes, episcleritis Spondyloarthritis (anterior uveitis), Sjögren's, Behçet's, GCA
Oral/genital Ulcers (painful vs. painless), dryness SLE (painless oral ulcers), Behçet's (painful oral and genital ulcers), Sjögren's
Respiratory Dyspnoea, cough, pleuritic chest pain RA-ILD, systemic sclerosis-ILD, SLE pleuritis, granulomatosis with polyangiitis
Cardiovascular Chest pain, claudication, DVT/PE history SLE (Libman-Sacks, accelerated atherosclerosis), vasculitis, APS
Renal Foamy urine, haematuria, oedema Lupus nephritis, vasculitis, amyloidosis, analgesic nephropathy
Neurological Paraesthesia, mononeuritis multiplex, seizures, headache Vasculitis, CNS lupus, SLE, entrapment neuropathy (RA, OA)
Constitutional Fatigue, weight loss, fevers, night sweats SLE, vasculitis, polymyalgia rheumatica, malignancy

Additional History Domains

  • Family history: RA, SLE, SpA (HLA-B27 associated), gout, psoriasis, autoimmune thyroid disease.
  • Medication history: Drug-induced lupus (hydralazine, procainamide, isoniazid, minocycline), gout precipitants (thiazides, loop diuretics, low-dose aspirin), statin myopathy.
  • Occupational and recreational history: Repetitive strain, vibration exposure, manual labour (OA risk), sexual history (gonococcal arthritis, reactive arthritis).
  • Smoking history: Strong risk factor for RA (especially seropositive RA) and worsens SLE and vasculitis outcomes.
  • Travel and infection history: Reactive arthritis (preceding GI or GU infection — Chlamydia, Salmonella, Shigella, Campylobacter, Yersinia), Lyme disease, Ross River virus, Barmah Forest virus (endemic in Australia).

Patterns of Arthritis

Recognising the pattern of joint involvement — number, symmetry, distribution, acuity, and associated features — is the cornerstone of rheumatological diagnosis. The five major patterns are summarised below.

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is a chronic systemic autoimmune inflammatory arthritis characterised by symmetric polyarthritis of small joints, with potential for progressive joint destruction, deformity, and extra-articular manifestations.

  • Pattern: Symmetric polyarthritis; small joints of hands (MCP, PIP, wrists) and feet (MTP) predominantly affected; larger joints (shoulders, knees, ankles, cervical spine) may be involved later.
  • class="guideline-li">Onset: Insidious over weeks to months; occasionally acute.
  • Key features: Morning stiffness > 1 hour; soft-tissue (synovial) swelling; sparing of DIP joints; ulnar deviation, swan-neck deformity, boutonnière deformity, Z-thumb in advanced disease; rheumatoid nodules (olecranon, extensor surfaces).
  • Serology: Rheumatoid factor (RF) positive in ~70%; anti-CCP antibodies more specific (~95%). Seronegative RA (RF/anti-CCP negative) occurs in ~30%.
  • Extra-articular: Rheumatoid nodules, interstitial lung disease, scleritis/episleritis, Felty syndrome (RA + splenomegaly + neutropenia), atlanto-axial subluxation, secondary amyloidosis.
🚨
Cervical spine caution: Atlanto-axial subluxation can occur in RA due to erosion of the transverse ligament of the atlas. Before intubation or cervical manipulation in any RA patient, ensure cervical spine imaging (flexion-extension lateral X-rays) has been performed. Subluxation > 3 mm is clinically significant.

Osteoarthritis

Osteoarthritis (OA) is the most common joint disease in Australia, characterised by degeneration of articular cartilage and remodelling of subchondral bone. It is primarily a disease of "wear and tear" but has inflammatory components.

  • Pattern: Asymmetric; weight-bearing joints (hips, knees) and DIP joints, PIP joints, first CMC, first MTP; sparing of MCPs, wrists, ankles.
  • Onset: Gradual over years; typically age > 50.
  • Key features: Bony hard swelling (Heberden's nodes at DIP, Bouchard's nodes at PIP); crepitus on movement; stiffness < 30 minutes; pain worsened by activity, relieved by rest; reduced range of motion; no systemic features.
  • Distinguishing from inflammatory arthritis: No warmth or erythema (unless acute flare); no morning stiffness > 1 hour; normal ESR/CRP; no synovitis on examination.

Seronegative Spondyloarthritis

The spondyloarthropathies (SpA) share common features: axial skeleton involvement, peripheral asymmetric oligoarthritis (predominantly lower limb), enthesitis, dactylitis, absence of rheumatoid factor, and association with HLA-B27. The group includes:

Subtype Key Distinguishing Features Classic Joint Pattern
Ankylosing spondylitis Chronic back pain > 3 months, onset < 40, improves with exercise; sacroiliitis on imaging; HLA-B27 positive in ~90% Axial predominant; bilateral sacroiliitis; peripheral joints in ~30%
Psoriatic arthritis Psoriasis (skin/nails); nail pitting, onycholysis; dactylitis; DIP involvement; arthritis mutilans (rare) Asymmetric oligo- or polyarthritis; DIP joints; can mimic RA
Reactive arthritis Preceding GI or GU infection (1–4 weeks prior); classic triad: arthritis + urethritis + conjunctivitis (Reiter's syndrome) Asymmetric oligoarthritis; large joints of lower limb; enthesitis
Enteropathic arthritis Associated with inflammatory bowel disease (Crohn's, UC); peripheral arthritis correlates with bowel disease activity; axial disease independent Type 1: large-joint asymmetric oligoarthritis; Type 2: small-joint symmetric polyarthritis
Undifferentiated SpA Incomplete features of any above subtype; inflammatory back pain + ≥ 1 SpA feature Variable

Gout

Gout is the most common inflammatory arthritis in Australia, caused by deposition of monosodium urate (MSU) crystals in joints and soft tissues due to chronic hyperuricaemia. It progresses through four clinical phases.

Phase 1
Asymptomatic Hyperuricaemia
Elevated serum urate (> 0.42 mmol/L in men, > 0.36 mmol/L in women) without symptoms. Crystal deposition may already be occurring. Treatment of asymptomatic hyperuricaemia alone is not routinely recommended in Australia.
Setting: Primary care monitoring
Phase 2
Acute Gout Flare
Sudden-onset severe monoarthritis (classically first MTP — "podagra"), maximal intensity within 12–24 hours; dramatic erythema, swelling, warmth; may be triggered by alcohol, purine-rich meals, dehydration, surgery, or medications. Self-limiting over 7–14 days if untreated.
Setting: ED / urgent primary care
Phase 3
Intercritical Gout
Asymptomatic intervals between flares. Flares become more frequent, polyarticular, and prolonged over time. Urate crystal deposition continues. Optimal window for urate-lowering therapy initiation.
Setting: Rheumatology / primary care
Phase 4
Chronic Tophaceous Gout
Tophi (chalky white deposits of MSU crystals) in joints, bursae, tendons, ear helix; chronic destructive arthropathy; joint deformity; renal urate stones. Tophi may erode bone on X-ray ("rat-bite" erosions with overhanging edges).
Setting: Rheumatology specialist
⚠️
Gold standard diagnosis: Identification of MSU crystals in synovial fluid or tophus aspirate under polarised light microscopy (negatively birefringent, needle-shaped crystals) is the definitive diagnostic test. Joint aspiration should be performed whenever feasible, especially to exclude septic arthritis, which can coexist with gout.

Pseudogout (Calcium Pyrophosphate Deposition Disease — CPPD)

CPPD is caused by deposition of calcium pyrophosphate dihydrate (CPP) crystals in articular cartilage and periarticular tissues. It is the second most common crystal arthropathy and prevalence increases with age.

  • Pattern: Acute monoarthritis or oligoarthritis; most commonly affects the knee, but also wrists, shoulders, ankles, and elbows.
  • Distinguishing features from gout: Knee is the most commonly affected joint (vs. first MTP in gout); crystals are weakly positively birefringent, rhomboid-shaped (vs. negatively birefringent needle-shaped MSU crystals); chondrocalcinosis visible on X-ray (cartilage calcification, particularly in knees, symphysis pubis, wrists).
  • Associations: Hyperparathyroidism, haemochromatosis, hypomagnesaemia, hypophosphatasia, familial CPPD.

Rapid Pattern Recognition Summary

Pattern Joints Affected Symmetry Stiffness Key Distinguisher
RA MCP, PIP, wrists, MTP Symmetric > 1 hour Spares DIP; soft-tissue swelling; RF/anti-CCP
OA DIP, PIP, 1st CMC, knees, hips Asymmetric < 30 min Bony swelling; crepitus; no warmth
SpA SI joints, spine, knees, ankles Asymmetric > 1 hour Inflammatory back pain; enthesitis; dactylitis; HLA-B27
Gout 1st MTP, midfoot, ankle, knee Asymmetric Variable Acute severe onset; dramatic erythema; MSU crystals
CPPD Knee, wrist, shoulder Often asymmetric Variable Knee predominant; chondrocalcinosis; CPP crystals
SLE MCP, PIP, wrists (non-erosive) Symmetric Variable Jaccoud's arthropathy (reducible deformity); non-erosive

Examination of Individual Joints

A systematic joint examination follows a consistent approach for each joint: look (inspect)feel (palpate)move (assess range of motion)special tests. Always compare with the contralateral joint. Assess for warmth, swelling (synovitis vs. effusion vs. bony), tenderness, deformity, range of motion (active and passive), crepitus, and instability.

💡
General approach: Begin the examination with the patient relaxed and comfortable. Examine each joint in turn, working systematically from the hands to the feet. Assess the patient's gait and posture. Always examine the joint above and below the symptomatic joint to identify referred pathology.

Hands and Wrists

The hands are the single most informative region in rheumatological examination. Both dorsal and palmar surfaces must be inspected and palpated.

  • Inspect: Symmetry of involvement; pattern of swelling (synovitis of MCP/PIP vs. bony enlargement of DIP); deformities (swan-neck, boutonnière, ulnar deviation, Z-thumb, Heberden's/Bouchard's nodes); muscle wasting (interossei, thenar, hypothenar); skin changes (rheumatoid nodules, sclerodactyly, psoriatic nail changes — pitting, onycholysis, oil-drop sign); tendon xanthomata.
  • Feel: Synovitis — boggy, doughy swelling in the joint line that does not transilluminate; effusion — fluctuant swelling that may transilluminate; bony enlargement — hard, irregular; warmth over joints (use dorsum of your hand).
  • Move: Assess each joint through full range: MCP flexion/extension, PIP flexion/extension, thumb opposition and CMC movements, wrist flexion/extension, radial/ulnar deviation. Grip strength (sphygmomanometer cuff inflated to 20 mmHg — normal > 200 mmHg in women, > 300 mmHg in men).
  • Special tests: Phalen's test and Tinel's sign for carpal tunnel syndrome (common in RA, hypothyroidism, pregnancy); Finkelstein's test for de Quervain's tenosynovitis; piano key test for DRUJ instability.

Elbows

  • Inspect: Fixed flexion deformity (loss of the normal 5–15° carrying angle); olecranon bursitis (swelling over the olecranon); rheumatoid nodules on the extensor surface; tophi.
  • Feel: Palpate the joint line; assess for synovitis (bulging either side of the olecranon); palpate the olecranon bursa; assess medial and lateral epicondyles for tenderness (medial/lateral epicondylitis).
  • Move: Flexion (0–150°), extension, supination, pronation. Loss of terminal extension is the earliest sign of elbow pathology.

Shoulders

  • Inspect: Symmetry; muscle wasting (supraspinatus, infraspinatus — axillary nerve); scapular winging; visible swelling.
  • Feel: Bicipital groove tenderness (bicipital tendinopathy); acromioclavicular joint tenderness; subacromial tenderness; glenohumeral joint (palpate anteriorly in the interval between coracoid process and humeral head).
  • Move: Active and passive flexion, extension, abduction, adduction, internal and external rotation. Assess for painful arc (60–120° abduction — subacromial impingement/rotator cuff pathology). Test rotator cuff strength: supraspinatus (empty can test), infraspinatus (resisted external rotation), subscapularis (internal rotation — lift-off test).
  • Special tests: Hawkins–Kennedy and Neer's impingement signs; scarf test for AC joint pathology.

Spine (Cervical, Thoracic, Lumbar, Sacroiliac)

  • Cervical spine: Range of motion (flexion, extension, lateral flexion, rotation); tenderness over spinous processes and facet joints; Spurling's test (cervical radiculopathy); examine for atlanto-axial instability in RA.
  • Thoracic spine: Tenderness on palpation; assess chest expansion (normal ≥ 5 cm; reduced in ankylosing spondylitis — a key sign).
  • Lumbar spine: Schober's test (mark skin at L5, mark 10 cm above; on maximal forward flexion, the distance should increase by ≥ 5 cm; < 5 cm indicates restricted lumbar flexion — ankylosing spondylitis); modified Schober's; fingertip-to-floor distance; lumbar lateral flexion.
  • Sacroiliac joints: Tenderness on direct palpation; FABER (Patrick's) test (flexion, abduction, external rotation — positive if reproduces buttock/posterior thigh pain suggestive of sacroiliitis); Gaenslen's test (hyperextension of one hip while the other is flexed — stresses the SI joint); compression/distraction tests.

Hips

  • Inspect: Gait (antalgic, Trendelenburg — abductor weakness); leg length discrepancy; posture.
  • Feel: Direct palpation of the hip joint is difficult as it is deep. Greater trochanteric tenderness (trochanteric bursitis/lateral hip pain — common, especially in middle-aged women). ASIS tenderness.
  • Move: Flexion (0–120°), extension (0–30°), abduction (0–45°), adduction (0–30°), internal and external rotation (assessed with hip and knee flexed to 90°). Loss of internal rotation is the earliest sign of hip OA.
  • Special tests: FABER/Patrick's test; Thomas test for fixed flexion deformity (flex the contralateral hip to flatten the lumbar lordosis — if the ipsilateral thigh rises off the bed, a fixed flexion deformity is present); log roll test (gentle internal/external rotation — most sensitive provocative test for intra-articular hip pathology); Trendelenburg test.

Knees

  • Inspect: Swelling — generalised (effusion) vs. localised (Baker's cyst, prepatellar bursa); alignment — valgus, varus; quadriceps wasting; popliteal fullness (Baker's cyst).
  • Feel: Assess for warmth; palpate for effusion (patellar tap test — press the patella sharply downward against the femur and feel for ballottement; sweep test — milk fluid from the suprapatellar pouch medially, then sweep laterally and observe a fluid wave); joint line tenderness (meniscal pathology); patellar tenderness.
  • Move: Flexion (0–135°), extension (0°; hyperextension may indicate ligamentous laxity). Assess for crepitus with patellofemoral movement.
  • Special tests: Anterior drawer and Lachman's test (ACL); posterior drawer (PCL); McMurray's test (meniscal tear); valgus/varus stress tests (MCL/LCL stability).

Feet and Ankles

  • Inspect: First MTP joint (gout — acute erythema and swelling; hallux valgus); MTP joints dorsally (RA synovitis — early and common site); forefoot deformity (claw toes, hammer toes, metatarsal head subluxation); hindfoot alignment; midfoot swelling; callosities over pressure points; tophi (first MTP, Achilles tendon, helix of ear); nail changes (psoriasis).
  • Feel: Squeeze across the MTPs (MTP squeeze test — tenderness suggests early inflammatory arthritis); palpate each MTP individually; palpate the subtalar joint; assess for ankle synovitis (swelling anterior to the malleoli); Achilles tendon tenderness (enthesitis — SpA; Achilles tendinopathy).
  • Move: Ankle dorsiflexion (0–20°), plantarflexion (0–50°), inversion, eversion; MTP extension (great toe extension — loss in hallux rigidus/OA; "too many toes" sign in hindfoot valgus).
  • Special tests: Squeeze test (MTP compression — early RA); Homan's sign (unreliable for DVT); Thompson test (Achilles tendon rupture).

Signs of Systemic Connective Tissue Disease

Systemic connective tissue diseases (CTDs) are multi-system autoimmune disorders with overlapping clinical features. Recognition of their characteristic clinical signs is essential for early diagnosis and referral to rheumatology. The major CTDs and their hallmark signs are described below.

Systemic Lupus Erythematosus (SLE)

SLE is a chronic systemic autoimmune disease characterised by production of autoantibodies (particularly anti-dsDNA, anti-Smith) and immune complex deposition, causing inflammation in virtually any organ system.

System Key Clinical Signs
Skin Malar (butterfly) rash — spares nasolabial folds; discoid rash (scarring, follicular plugging); photosensitivity; oral ulcers (typically painless on hard palate); alopecia (diffuse, non-scarring); livedo reticularis; Raynaud's phenomenon
Musculoskeletal Non-erosive polyarthritis; Jaccoud's arthropathy (reducible deformity — ulnar deviation, swan-neck — without erosions on X-ray); avascular necrosis (femoral head); myositis
Renal Lupus nephritis — proteinuria, haematuria, casts, declining GFR; classified by ISN/RPS (Class I–VI); renal biopsy essential for classification and treatment
Haematological Haemolytic anaemia; leucopenia (< 4 × 10⁹/L); lymphopenia (< 1 × 10⁹/L); thrombocytopenia (< 100 × 10⁹/L); antiphospholipid antibodies
Cardiovascular Pericarditis; Libman-Sacks endocarditis (verrucous vegetations on mitral valve); accelerated atherosclerosis
Neuropsychiatric Seizures; psychosis; cognitive dysfunction; cerebrovascular events; mononeuritis multiplex
Serositis Pleurisy; pericarditis; peritonitis (less common)
💡
Classification criteria: The 2019 EULAR/ACR classification criteria for SLE require a positive ANA (≥ 1 : 80) as an entry criterion, followed by weighted scoring across clinical and immunological domains. A score ≥ 10 classifies as SLE. This is more sensitive and specific than the older 1997 ACR criteria.

Systemic Sclerosis (Scleroderma)

Systemic sclerosis is characterised by fibrosis of the skin and internal organs, vasculopathy, and autoimmune activation. Two major subsets exist:

Limited
Limited Cutaneous Systemic Sclerosis (lcSSc)
Skin thickening limited to fingers, hands, forearms, feet, and distal lower legs. Previously called CREST syndrome (Calcinosis, Raynaud's, oEsophageal dysmotility, Sclerodactyly, Telangiectasia). Anti-centromere antibodies in ~70%. Pulmonary arterial hypertension is the major long-term risk. Generally slower progression.
Setting: Rheumatology outpatient
Diffuse
Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Proximal skin thickening (trunk, upper arms, thighs) in addition to distal. Anti-Scl-70 (anti-topoisomerase I) antibodies. Higher risk of interstitial lung disease, scleroderma renal crisis, and cardiac involvement. More aggressive course with significant morbidity and mortality.
Setting: Rheumatology specialist

Key examination signs:

  • Sclerodactyly: Thick, tight, waxy skin over the fingers with reduced ability to pinch the skin.
  • Telangiectasia: Small red macules on the face, lips, hands, and mucous membranes.
  • Calcinosis: Subcutaneous calcium deposits, particularly over the fingers, elbows, and knees.
  • Digital pitting and ulcers: Small scars on the fingertips from ischaemic damage; digital ulcers may become infected or gangrenous.
  • Nail-fold capillaroscopy: Dilated capillary loops, haemorrhages, and avascular areas — characteristic "scleroderma pattern." Perform with an ophthalmoscope or dermatoscope at 20× magnification.
  • Microstomia: Reduced oral aperture due to perioral skin tightening.
  • Beak-like nose.
🚨
Scleroderma renal crisis: Acute onset of severe hypertension (often > 200/120 mmHg), oliguria, microangiopathic haemolytic anaemia (MAHA), and rapidly progressive renal failure. Occurs most commonly in dcSSc with anti-RNA polymerase III antibodies. Treat immediately with ACE inhibitors (e.g., ramipril, perindopril). This is a rheumatological emergency.

Sjögren's Syndrome

Sjögren's syndrome is a chronic autoimmune exocrinopathy causing lymphocytic infiltration and destruction of salivary and lacrimal glands. It may occur as a primary condition or secondary to another CTD (most commonly RA).

  • Key signs: Bilateral parotid gland enlargement (may be intermittent or persistent); keratoconjunctivitis sicca (reduced tear meniscus, corneal staining with fluorescein or rose bengal); dental caries (often rampant); angular cheilitis; dry cracked tongue; vaginal dryness.
  • Extra-glandular: Arthralgia/arthritis; interstitial lung disease; renal tubular acidosis (type 1 — distal); peripheral neuropathy; increased risk of B-cell lymphoma (particularly MALT lymphoma — 5–10% lifetime risk, 15–20× general population).
  • Serology: Anti-SSA/Ro (present in ~70% of primary Sjögren's); anti-SSB/La (more specific but less sensitive); ANA; RF positive in ~70%. Anti-SSA/Ro antibodies cross the placenta and are associated with neonatal lupus and congenital heart block.

Vasculitis

Vasculitis encompasses a heterogeneous group of disorders characterised by inflammation of blood vessel walls, leading to tissue ischaemia and organ damage. Clinical signs vary with vessel size.

Vessel Size Condition Key Clinical Signs
Large vessel Giant cell arteritis (GCA) New headache (temporal); jaw claudication; scalp tenderness; temporal artery thickening/reduced pulsation; visual disturbance (anterior ischaemic optic neuropathy — medical emergency); polymyalgia rheumatica (proximal shoulder/hip girdle pain and stiffness) coexists in ~50%
Large vessel Takayasu arteritis Arm claudication; blood pressure discrepancy between arms (> 10 mmHg); absent pulses; bruits over arteries; aortic regurgitation
Medium vessel Polyarteritis nodosa (PAN) Livedo reticularis; digital gangrene; mononeuritis multiplex; testicular pain; renal involvement (hypertension, not glomerulonephritis); mesenteric ischaemia
Small vessel ANCA-associated vasculitis (GPA, MPA, EGPA) Palpable purpura; nasal craters/saddle-nose deformity (GPA); pulmonary haemorrhage; glomerulonephritis (rapidly progressive); mononeuritis multiplex; asthma + eosinophilia (EGPA)
Small vessel IgA vasculitis (Henoch-Schönlein purpura) Palpable purpura (lower limbs and buttocks); arthralgia; abdominal pain; glomerulonephritis
🚨
Giant cell arteritis — vision threat: Any patient aged > 50 with new-onset headache, jaw claudication, scalp tenderness, or visual symptoms must be assessed urgently for GCA. If GCA is suspected, commence high-dose prednisolone (50–100 mg PO daily) immediately — do not wait for temporal artery biopsy. Arrange urgent rheumatology/ophthalmology review. Delay in treatment risks permanent blindness.

Inflammatory Myositis (Polymyositis / Dermatomyositis)

The idiopathic inflammatory myopathies are autoimmune conditions causing chronic muscle inflammation and weakness. Dermatomyositis (DM) has characteristic skin findings; polymyositis (PM) has muscle inflammation without pathognomonic skin changes. Inclusion body myositis (IBM) is a distinct entity affecting older males.

  • Muscle weakness: Proximal, symmetric, progressive; difficulty rising from a chair, climbing stairs, lifting arms overhead (getting items from high shelves), rising from the floor. Distal muscles relatively spared until late.
  • Dermatomyositis-specific skin signs: Gottron's papules (violaceous papules over the MCP and IP joints — pathognomonic); heliotrope rash (purple discolouration of the upper eyelids with periorbital oedema); V-sign (erythema over the anterior chest and neck); shawl sign (erythema over the shoulders and upper back); mechanic's hands (rough, cracked, hyperkeratotic lateral aspects of the fingers); periungual erythema and telangiectasia.
  • Mechanic's hands are associated with anti-synthetase syndrome (anti-Jo-1), which also features interstitial lung disease, arthritis, Raynaud's phenomenon, and fever.
  • Malignancy association: Dermatomyositis (especially in adults over 40) is associated with underlying malignancy (ovarian, lung, pancreatic, colorectal, gastric, lymphoma). Age-appropriate cancer screening is mandatory at diagnosis. This association is weaker in polymyositis.
  • Childhood DM: Most common idiopathic inflammatory myopathy in children; calcinosis is common; vasculopathy may cause GI ulceration. Requires specialist paediatric rheumatology management.

Overlapping Features and Mixed Connective Tissue Disease

Many CTDs have overlapping features, and patients may present with elements of more than one condition. Mixed connective tissue disease (MCTD) is characterised by overlapping features of SLE, systemic sclerosis, and polymyositis, with high-titre anti-U1 RNP antibodies. Features include Raynaud's phenomenon, swollen "sausage" fingers (puffy hands), sclerodactyly, inflammatory myositis, and arthritis. The "undifferentiated CTD" label applies to patients with suggestive features who do not meet criteria for a defined CTD.

Bedside Assessment Summary for Connective Tissue Disease

1
General inspection
Rash distribution, alopecia, livedo reticularis, digital ulcers, sclerodactyly, telangiectasia, calcinosis, muscle wasting
2
Skin and nails
Malar rash, discoid lesions, Gottron's papules, heliotrope rash, mechanic's hands, psoriatic nail changes, nail-fold capillaroscopy
3
Oral cavity
Painless hard palate ulcers (SLE), oral dryness, dental caries, parotid enlargement, microstomia
4
Eyes
Conjunctival pallor, scleritis/episcleritis, keratoconjunctivitis sicca, temporal artery tenderness
5
Cardiorespiratory
Pericardial rub, pulmonary crackles (ILD), signs of PAH, blood pressure measurement (scleroderma renal crisis)
6
Neurological
Mononeuritis multiplex (vasculitis), peripheral neuropathy, cognitive assessment (CNS lupus), proximal muscle power (myositis)

Investigations

Investigations in rheumatology should be guided by the clinical pattern identified on history and examination. The following are the key first-line and confirmatory investigations, with Australian availability notes.

Essential
FBC, ESR, CRP, UEC, LFT
Available at all Australian pathology services. FBC may show anaemia of chronic disease, leucopenia, thrombocytopenia (SLE). ESR and CRP assess inflammatory activity — ESR often elevated in RA, PMR; CRP more responsive to change.
Essential
Rheumatoid factor (RF) and anti-CCP antibodies
Anti-CCP has ~95% specificity for RA and is part of the 2010 ACR/EULAR RA classification criteria. RF is less specific (positive in Sjögren's, infections, healthy elderly). MBS item 6939 (autoantibody testing).
Essential
ANA (antinuclear antibody) with titre and pattern
Screening test for CTDs. High titre (≥ 1 : 160) with homogeneous pattern suggests SLE; centromere pattern suggests limited SSc; nucleolar pattern suggests diffuse SSc. Low-titre ANA is common in healthy individuals — must be interpreted in clinical context. MBS item 6938.
Available
ENA panel (anti-dsDNA, anti-Smith, anti-SSA/Ro, anti-SSB/La, anti-Scl-70, anti-centromere, anti-Jo-1, anti-U1 RNP)
Requested based on ANA result and clinical suspicion. Anti-dsDNA titres correlate with SLE disease activity (especially lupus nephritis). All available at major Australian pathology providers (Sullivan Nicolaides, Douglass Hanly Moir, Pathology West).
Available
ANCA (c-ANCA/PR3, p-ANCA/MPO)
For suspected vasculitis (GPA, MPA, EGPA). c-ANCA/PR3 associated with GPA; p-ANCA/MPO with MPA and EGPA. Available at reference laboratories.
Essential
Serum urate
Elevated in gout (> 0.42 mmol/L men, > 0.36 mmol/L women), but may be normal during an acute flare. Useful for monitoring urate-lowering therapy.
Essential
Synovial fluid aspiration and analysis
Gold standard for crystal arthropathies and septic arthritis. Assess cell count (> 2,000/μL suggests inflammatory; > 50,000/μL suggests septic arthritis or crystal arthritis), Gram stain and culture, and crystal analysis under polarised light microscopy. Available at hospitals and many GP practices with joint aspiration skills.
Available
HLA-B27
Supports diagnosis of spondyloarthropathy when clinical features are present. Positive in ~90% of ankylosing spondylitis, ~60% of reactive arthritis, ~50% of psoriatic arthritis, and ~8% of the general Australian Caucasian population. MBS item 6945.
Available
Imaging — X-rays (hands, feet, pelvis/SI joints, affected joints)
MBS item 58106 (single region). RA: periarticular osteopenia, joint space narrowing, marginal erosions (late). OA: joint space narrowing, osteophytes, subchondral sclerosis, subchondral cysts. SpA: bilateral sacroiliitis (graded I–IV), syndesmophytes, "bamboo spine." Gout: "rat-bite" erosions with overhanging edges. CPPD: chondrocalcinosis.
Referral
Musculoskeletal ultrasound
Increasingly available in rheumatology clinics and some GP practices in Australia. Highly sensitive for detecting synovitis, erosions (more sensitive than X-ray early), tenosynovitis, and enthesitis. Can guide corticosteroid injection. MBS items for specialist-requested MSK ultrasound available.
Specialist
MRI (sacroiliac joints, spine, affected joints)
Gold standard for early sacroiliitis (MRI shows bone marrow oedema before X-ray changes). MBS item 63086 (SI joints). Also useful for assessing RA (early erosions), avascular necrosis, and myositis (muscle oedema on STIR sequences). Requires specialist request.
Specialist
Nail-fold capillaroscopy
Performed by rheumatologists using ophthalmoscope, dermatoscope, or dedicated capillaroscope. Identifies scleroderma pattern (giant capillaries, haemorrhages, avascular areas) distinguishing primary from secondary Raynaud's.

Aboriginal and Torres Strait Islander Health Considerations

Aboriginal and Torres Strait Islander Health

Rheumatic and musculoskeletal diseases contribute significantly to the health gap experienced by Aboriginal and Torres Strait Islander Australians. Culturally safe assessment, early recognition, and appropriate referral pathways are essential.

Gout prevalence
Gout is more prevalent among Aboriginal and Torres Strait Islander Australians compared with non-Indigenous Australians, with higher rates of hospitalisation for gout flares. Contributing factors include higher rates of chronic kidney disease, obesity, type 2 diabetes, and limited access to urate-lowering therapy in remote communities. Serum urate monitoring and early initiation of allopurinol where indicated should be prioritised.
Rheumatic heart disease
Acute rheumatic fever (ARF) and rheumatic heart disease (RHD) remain significant causes of morbidity among Aboriginal and Torres Strait Islander Australians, particularly in Northern Territory, Far North Queensland, and northern Western Australia. ARF presents with migratory polyarthritis and must be distinguished from other inflammatory arthritides. The 2020 Australian RHD Guidelines (RHDAustralia) outline the revised Jones criteria for Aboriginal and Torres Strait Islander populations (which include lower thresholds for some criteria in high-risk populations). Secondary prophylaxis with benzathine penicillin G is critical.
Systemic lupus erythematosus
SLE tends to present earlier, with greater severity and more renal involvement among Aboriginal and Torres Strait Islander Australians compared with non-Indigenous Australians. Delayed diagnosis is common due to limited specialist access in remote areas. Any Aboriginal or Torres Strait Islander person with unexplained multi-system features (rash, arthritis, renal disease, cytopenias) should have SLE excluded.
Remote access barriers
Many Aboriginal and Torres Strait Islander Australians live in remote and very remote areas where specialist rheumatology services are absent. Rheumatology outreach clinics (e.g., Top End Health Service, Central Australian Health Service) and telehealth consultations via the Australian Telehealth Network are essential for reducing diagnostic delays. GP-led shared-care models with rheumatologist support are increasingly used.
Cultural safety
Use of culturally appropriate communication, including health literacy–appropriate explanations of arthritis, awareness of cultural obligations and kinship systems affecting appointment attendance, and the role of Aboriginal and Torres Strait Islander health workers as cultural brokers. Examination should respect cultural norms regarding touch, gender, and privacy. Ask — do not assume — about a patient's cultural identity and preferences.
Musculoskeletal infection
Septic arthritis and osteomyelitis are more common among Aboriginal and Torres Strait Islander Australians, particularly children in remote communities. Group A Streptococcus, Staphylococcus aureus (including CA-MRSA), and Kingella kingae are important pathogens. Any acute monoarthritis in this population requires joint aspiration to exclude septic arthritis.

Special Populations

🤰

Pregnancy

Many rheumatic conditions affect pregnancy planning: SLE may flare in the postpartum period; anti-SSA/Ro antibodies cross the placenta and risk neonatal lupus/congenital heart block; antiphospholipid syndrome increases risk of recurrent pregnancy loss.
Medications: hydroxychloroquine is safe and should be continued in pregnancy; methotrexate is absolutely contraindicated (teratogenic); azathioprine is considered safe; NSAIDs should be avoided in the third trimester (premature ductus arteriosus closure); prednisolone at low doses is generally safe.
Pre-conception counselling with rheumatology is strongly recommended for all women of childbearing age with CTD or inflammatory arthritis.
👶

Paediatrics

Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic condition in children (prevalence ~1 in 1,000). Classification includes oligoarticular, polyarticular (RF-positive and RF-negative), enthesitis-related, psoriatic, and systemic subtypes.
Uveitis (anterior) is asymptomatic and sight-threatening — regular slit-lamp screening is essential for oligoarticular JIA (anti-ANA positive patients at highest risk).
Childhood DM is the most common inflammatory myopathy in children; calcinosis is common and may be severe.
Acute rheumatic fever (migratory polyarthritis) must be considered in Aboriginal and Torres Strait Islander children in endemic regions.
👴

Elderly

Polymyalgia rheumatica (PMR) is common in patients > 65 — bilateral shoulder and hip girdle pain and stiffness, ESR often > 40 mm/h, dramatic response to low-dose prednisolone (15 mg). Always consider GCA overlap.
Elderly-onset RA may present differently — acute onset, large-joint predominant, constitutional symptoms; may mimic PMR.
CPPD prevalence increases markedly with age; chondrocalcinosis is found in up to 30% of people > 80 on X-ray.
Medication considerations: increased susceptibility to corticosteroid side effects (osteoporosis, diabetes, infections, delirium); NSAID risks (GI bleeding, renal impairment, cardiovascular events); methotrexate requires careful renal dosing.
🫘

Renal Impairment

Chronic kidney disease (CKD) is prevalent among Aboriginal and Torres Strait Islander Australians and affects gout management (reduced urate clearance; allopurinol dose adjustment required; avoid NSAIDs).
Lupus nephritis is a major cause of morbidity in SLE; renal biopsy classification guides treatment.
Many DMARDs require renal dose adjustment: methotrexate is contraindicated if eGFR < 15 mL/min; mycophenolate requires monitoring; allopurinol must be started at low dose (50 mg daily) and titrated slowly in CKD.
🫁

Hepatic Impairment

Methotrexate, leflunomide, and azathioprine are hepatotoxic — baseline and serial LFT monitoring is required. Contraindicated in significant hepatic impairment.
Hepatitis B and C must be screened for prior to immunosuppression, as biologic DMARDs may cause viral reactivation. Hepatitis B is more prevalent in some Aboriginal and Torres Strait Islander communities.
Corticosteroids may exacerbate non-alcoholic fatty liver disease.
🛡️

Immunocompromised

Patients on DMARDs and biologic agents are at increased risk of infection — tuberculosis screening (QuantiFERON-Gold) is mandatory before commencing TNF inhibitors (adalimumab, etaneriff, infliximab, certolizumab, golimumab).
Live vaccines (MMR, varicella, zoster [Zostavax]) are contraindicated on immunosuppressive therapy. Shingrix (recombinant) is safe and recommended.
Pneumococcal and influenza vaccination should be up to date prior to commencing immunosuppression. COVID-19 vaccination is recommended and may require additional doses in immunosuppressed patients per ATAGI guidelines.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Arthritis and other musculoskeletal conditions. AIHW, Canberra; 2024.
  2. 2. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62(9):2569–2581.
  3. 3. Petri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677–2686.
  4. 4. Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9):1151–1159.
  5. 5. Neogi T, Jansen TL, Dalbeth N, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2015;74(10):1789–1798.
  6. 6. Rudwaleit M, van der Heijde D, Landewé R, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70(1):25–31.
  7. 7. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–1755.
  8. 8. Shiboski CH, Shiboski SC, Seror R, et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome. Ann Rheum Dis. 2017;76(1):9–16.
  9. 9. Lundberg IE, Tjärnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017;76(12):1955–1964.
  10. 10. RHDAustralia (ARF/RHD writing group). The 2020 Australian guideline for prevention, diagnosis and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Menzies School of Health Research, Darwin; 2020.
  11. 11. Royal Australian College of General Practitioners (RACGP). Guideline for the management of knee and hip osteoarthritis. 2nd ed. RACGP, Melbourne; 2018.
  12. 12. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017;76(1):29–42.
  13. 13. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990;33(8):1122–1128.
  14. 14. Australian Rheumatology Association (ARA). Biologics and biosimilars in rheumatology: ARA position statement. ARA, Sydney; 2023.
  15. 15. Buchbinder R, Batterham R, Cicuttini F, et al. Musculoskeletal conditions in Australia: a snapshot. Aust J Gen Pract. 2020;49(12):812–816.
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).
for PBS-listed medicines at participating pharmacies.
Cultural safety
Engagement with Aboriginal Community Controlled Health Organisations (ACCHOs) is essential. Cultural safety training for non-Indigenous clinicians, use of Aboriginal Health Workers and Liaison Officers, and incorporation of traditional healing practices alongside Western medicine improve treatment adherence and outcomes. Avoidance of eye contact, respect for gender-sensitive examination practices, and understanding of sorry business protocols are critical elements of culturally safe care.
Medication adherence
Complex DMARD regimens with frequent monitoring requirements present adherence challenges. Long-acting depot injections (e.g., methotrexate SC) may improve adherence compared to oral regimens. Community pharmacy partnerships through the Indigenous Pharmacy Programmes improve medication management.
Specific conditions
Rheumatic heart disease (RHD) requires secondary prophylaxis with benzathine penicillin G (BPG) 1.2 MU IM every 3–4 weeks for a minimum of 10 years or until age 21 (whichever is longer). RHD registers (e.g., NT RHD Register) facilitate recall and follow-up. The Australian RHD Endgame Strategy targets elimination by 2031.
Referral pathways
Referral through ACCHOs and Aboriginal Hospital Liaison Officers (AHLOs) improves engagement. The Specialist Outreach Assistance Programme provides funded specialist visits to remote communities. NT, WA, and QLD have specific rheumatology outreach programmes targeting Indigenous communities.

📚 References

  1. 1. Australian Institute of Health and Welfare (AIHW). Autoimmune disease in Australia. Cat. no. PHE 312. Canberra: AIHW; 2023.
  2. 2. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res. 2021;73(7):924–939.
  3. 3. Fanouriakis A, Kostopoulou M, Alber K, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736–745.
  4. 4. Chung SA, Langford CA, Maz M, et al. 2021 American College of Rheumatology/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res. 2021;73(11):1583–1599.
  5. 5. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3–18.
  6. 6. Australian Technical Advisory Group on Immunisation (ATAGI). Australian Immunisation Handbook. Australian Government Department of Health; 2024. Available from: immunisationhandbook.health.gov.au.
  7. 7. Rheumatic Heart Disease Australia (RHDAustralia). The 2020 Australian guideline for prevention, diagnosis, and management of acute rheumatic fever and rheumatic heart disease. 3rd ed. Darwin: Menzies School of Health Research; 2020.
  8. 8. Pharmaceutical Benefits Scheme (PBS). PBS Schedule. Australian Government Department of Health. Available from: pbs.gov.au. Accessed 2024.
  9. 9. Agarwal S, Cunnington J, Nossent J. Autoimmune disease in Indigenous Australians: a systematic review. Int J Rheum Dis. 2021;24(12):1487–1498.
  10. 10. Pisetsky DS. Antinuclear antibody testing — misunderstood or misused? Clin Immunol. 2023;255:109717.
  11. 11. Bertsias GK, Tektonidou M, Amoura Z, et al. Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771–1782.
  12. 12. Ledingham J, Deighton C; British Society for Rheumatology Standards, Audit and Guidelines Working Group. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis. Rheumatology. 2005;44(2):155–158.
  13. 13. National Health and Medical Research Council (NHMRC). National statement on ethical conduct in human research. Canberra: NHMRC; 2023 (updated).